Qiagen N.V. (QGEN) Rolls Out QIAstat-Dx Rise, Expands U.S. Testing Access

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Qiagen N.V. is one of them.

Qiagen N.V. (NYSE:QGEN), a global leader in molecular diagnostics and sample preparation, continues to expand its precision medicine footprint through innovative testing solutions for infectious diseases, cancer genomic profiling, and cell and gene therapy quality control.

In Q2 2025, the business reported 7% net sales growth year-over-year, driven by strong adoption of key products such as QIAstat-Dx and QuantiFERON. The company plans to launch three new instruments starting in late 2025, aiming to enhance diagnostic capabilities and support future growth.

Qiagen N.V. (NYSE:QGEN) has also advanced its precision oncology portfolio with new QIAseq panels that enable fast, comprehensive cancer genomic profiling, reducing hands-on time and improving cost-effectiveness for laboratories. Additional innovations include the QIAseqHYB Read Panels for long-read sequencing, which address complex genomic regions and support a wide range of next-generation sequencing platforms.

A major milestone in 2025 is the FDA clearance and commercial rollout of QIAstat-Dx Rise, expected to expand diagnostic access and testing capacity, particularly in the U.S. healthcare market. These developments reinforce Qiagen N.V. (NYSE:QGEN)’s strategy of strengthening its molecular diagnostics offerings and expanding its role in precision medicine and biotherapeutic development.

While we acknowledge the potential of QGEN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.